Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

gender (1)


Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page




    COVID-19 MESHD-Related Abnormal Liver Enzymes Levels: A Retrospective Study

    Authors: Jian-dan Qian; Yan Wang; Tian-tian Yao; Hai-chao Li; gui-qiang Wang

    doi:10.21203/rs.3.rs-36830/v1 Date: 2020-06-19 Source: ResearchSquare

    Background: A new disease called Coronavirus disease MESHD ( COVID-19 MESHD) related to SARS-CoV-2 has brought serious attacks to the world. It causes damage to multiple organ systems of the body include liver. Here we intend to shed light on the clinical features its mechanism related to liver damage which caused by COVID-19 MESHD.Methods: Clinical records and laboratory results were obtained from 138 patients with laboratory-confirmed COVID-19 MESHD who were admitted to Tongji hospital, Wuhan, China from February 8, 2020 to February 18, 2020. Information on clinical features of patients with abnormal liver tests were collected for analysis.Results: Fifty-four (39.1%) and eighty-three (60.1%) patients had abnormal liver enzyme levels on admission and during the course of disease. Hepatocyte type was more common than cholestatic type abnormal MESHD. 24(17.4%) patients reached the liver injury MESHD standard in the course of disease. Patients with abnormal liver enzyme levels were more likely to be male TRANS, had higher levels of inflammation MESHD indicators, lower pulse oxygen saturation and lymphocyte count. There is a significantly higher proportion of abnormal liver enzymes levels in the patients which administrated antibiotics during hospitalization, compared with that in the ones without antibiotics therapy (56.6% vs 32.7%). Patients with liver injury MESHD was an independent predictor of a poor prognosis (p<0.0001, OR 7.774, 95%CI 2.674-22.599).Conclusions: Liver injury MESHD in COVID-19 MESHD patients was an independent predictor of a poor prognosis. The COVID-19 MESHD-related abnormal liver enzymes levels may be considered as the result of secondary liver damage caused mainly by several factors. Hypoxia MESHD and disease severity account for the largest proportion.

    Liver Chemistries in COVID-19 MESHD Patients with Survival or Death MESHD: A Meta-Analysis

    Authors: Qing-Qing Xing; Xuan Dong; Yan-Dan Ren; Wei-Ming Chen; Dan-Yi Zeng; Yan-Yan Cai; Mei-Zhu Hong; Jin-Shui Pan

    doi:10.1101/2020.04.26.20080580 Date: 2020-05-01 Source: medRxiv

    Background and Aims: Although abnormal liver chemistries are linked to higher risk of death related to coronavirus disease MESHD ( COVID-19 MESHD), liver manifestations may be diverse and even confused. Thus, we performed a meta-analysis of published liver manifestations and described the liver damage in COVID-19 MESHD patients with death MESHD or survival. Methods: We searched PubMed, Google Scholar, medRxiv, bioRxiv, Cochrane Library, Embase, and three Chinese electronic databases through April 22, 2020. We analyzed pooled data on liver chemistries stratified by the main clinical outcome of COVID-19 MESHD using a fixed or random-effects model. Results: In the meta-analysis of 18 studies, which included a total of 2,862 patients, the pooled mean alanine aminotransferase (ALT) was 30.9 IU/L in the COVID-19 MESHD patients with death MESHD and 26.3 IU/L in the COVID-19 MESHD patients discharged alive (p < 0.0001). The pooled mean aspartate aminotransferase (AST) level was 45.3 IU/L in the COVID-19 MESHD patients with death MESHD while 30.1 IU/L in the patients discharged alive (p < 0.0001). Compared with the discharged alive cases, the dead cases tended to have lower albumin levels but longer prothrombin time, and international standardized ratio. Conclusions: In this meta-analysis, according to the main clinical outcome of COVID-19 MESHD, we comprehensively described three patterns of liver impairment MESHD related to COVID-19 MESHD, hepatocellular injury MESHD, cholestasis HP cholestasis MESHD, and hepatocellular disfunction. Patients died from COVID-19 MESHD tend to have different liver chemistries from those are discharged alive. Close monitoring of liver chemistries provides an early warning against COVID-19 MESHD related death.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.